Table 1. Literature Review Summary.

Study	Location	Patient population	Number of patients	Vaccine	Full or partial vaccinationa	Seroconversion rateb
Addeo et al.	US, Europe	Solid tumors, hematologic malignancies	140	Pfizer Moderna	Full	94%
Agha et al.	US	Hematologic malignancies	67	Pfizer Moderna	Full	54%
Dhakal et al.	US	SCT (autologous, allogeneic), CAR T-cell therapy	130	Pfizer Moderna JJJ	Full	60%
Easdale et al.	UK	SCT (allogeneic)	55	Pfizer AZ	Partial	38%
Goshen-Lago et al.	Israel	Solid tumors	232	Pfizer	Full	86%
Herishanu et al.	Israel	CLL	167	Pfizer	Full	39.5%
Maneikis et al.	Lithuania	Hematologic malignancies, SCT (autologous, allogeneic)	857	Pfizer	Full	N/Ac
Palich et al.	France	Solid tumors	223	Pfizer	Full	94%
Roeker et al.	US	CLL	44	Pfizer Moderna	Full	52%
Thakkar et al.	US	Solid tumors, hematologic malignancies	200	Pfizer Moderna JJJ	Full	94%

Note. SCT = stem cell transplant; CAR = chimeric antigen receptor; CLL = chronic lymphocytic leukemia.

^aFull vaccination is defined as two doses of mRNA vaccine (Pfizer, Moderna), one dose of JJJ vaccine, or two doses of AZ vaccine. Partial vaccination is defined as one dose of Pfizer, Moderna, or AZ vaccines.

^bRate of anti-spike IgG seropositivity following vaccination.

^cNote: This study measured antibody titers, rather than seroconversion rates.